2 years ago By Tarikul — ZURICH, Nov 6 (Reuters) - Roche's (ROG.S) $20.7 billion move to buy back nearly a third of its voting stock from fellow Swiss drugmaker Novartis (NOVN.S) w

2 years ago By Flemming — ZURICH (Reuters) -Roche's family owners have been saved from having to make an expensive offer for the rest of the pharmaceuticals giant's shares after its

2 years ago By Poppy — Novartis (NYSE: NVS) agreed to sell its nearly one-third stake in Roche (Swiss: ROG) back to the company for around $20.7 billion. Why it matters: This is

2 years ago By Martin — Oct 26 (Reuters) - Novartis (NOVN.S) has raised the prospect of divesting its generic drugs unit Sandoz after years of revamping the business, saying on Tu

2 years ago By Suzana — Oct 26 (Reuters) - Novartis (NOVN.S) on Tuesday raised the prospect of divesting its generic drugs unit Sandoz and lifted its peak revenue estimate for its

3 years ago By Shannon — The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, in

3 years ago By Olachi — ZURICH, Sept 21 (Reuters) - Novartis (NOVN.S) has bought gene therapy specialist Arctos Medical to boost its efforts finding treatments for patients with s

3 years ago By Gesard — ZURICH, Aug 26 (Reuters) - Lonza (LONN.S) has appointed former Novartis (NOVN.S) executive Philippe Deecke as its new Chief Financial Officer, the Swiss ch

3 years ago By Shannon — Novartis, a key player in COVID-19 vaccine push, taps new chief legal officer

3 years ago By Yoongi — Novartis' canakinumab doesn't meet primary endpoint in phase III study